NCT05691660View on ClinicalTrials.gov

A Study of TAS3731 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Healthy Adult Males
Interventions
DRUG

TAS3731 Dose1

Oral administration,1 day,QD

DRUG

TAS3731 Dose2

Oral administration,7 days,QD

DRUG

TAS3731 Dose3

Oral administration,7 days,BID

DRUG

Placebo

Oral administration, 1 day,QD

DRUG

Placebo

Oral administration, 7 days,QD

DRUG

Placebo

Oral administration, 7 days,BID

Trial Locations (1)

Unknown

A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY